使用新型氧化酸化抑制剂来减弱人类质瘤的耐药性
Chia-Kuang Tsai1, Chin-Yu Lin2, Yung-Lung Chang2
1Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
EXCLI journal
|May 16, 2025
概括
多形质母细胞瘤 (GBM) 的治疗是具有挑战性的,因为temozolomide (TMZ) 的耐药性. 针对细胞能量生产的新药Gboxin有效抑制GBM生长,并在临床前模型中克服TMZ耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多形质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤.
- 泰莫佐洛米德 (TMZ) 耐药性,通常由O-6-甲基瓜宁-DNA甲基转移酶 (MGMT) 介导,限制了治疗疗效.
- 向氧化酸化 (OXPHOS) 是一种克服TMZ抗性的策略.
研究的目的:
- 评估新型OXPHOS抑制剂Gboxin对抗耐TMZ的GBM的疗效.
- 为了研究Gboxin在GBM细胞中的作用机制.
- 在临床前的GBM模型中评估Gboxin的治疗潜力.
主要方法:
- 在体外研究TMZ敏感和TMZ抗性GBM细胞系.
- 细胞增殖,细胞亡和OXPHOS活动的评估.
- 在GBM异种移植模型中的体内疗效研究.
主要成果:
- 在TMZ敏感和TMZ耐药的GBM细胞中,gboxin抑制了增殖和诱导了亡.
- 格博辛显著降低了GBM细胞中的OXPHOS活性.
- 在体内GBM模型中,Gboxin在体内GBM模型中证明了治疗效果,证实了其潜力.
结论:
- 格博辛是一种对GBM有前途的治疗药物,对TMZ敏感和TMZ抗性瘤都有效.
- 格博辛的机制包括抑制OXPHOS和诱导亡.
- 用Gboxin针对OXPHOS提供了一种可行的策略,以克服质母细胞瘤中temozolomide耐药性.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.0K
14:10Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
15.9K
相关概念视频
01:46Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K